Free Trial
NASDAQ:LUCD

Lucid Diagnostics Q3 2025 Earnings Report

Lucid Diagnostics logo
$1.18 -0.05 (-4.07%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$1.22 +0.04 (+2.97%)
As of 10/17/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lucid Diagnostics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Lucid Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.35 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lucid Diagnostics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Lucid Diagnostics Earnings Headlines

Forget AI, This Will Be the Next Big Tech Breakthrough
After picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...tc pixel
Lucid Diagnostics: Holding Onto Medicare Coverage Hopes
See More Lucid Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lucid Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lucid Diagnostics and other key companies, straight to your email.

About Lucid Diagnostics

Lucid Diagnostics (NASDAQ:LUCD) is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States. The company’s test is billed under existing procedural codes, and Lucid engages with payers to secure coverage and reimbursement. In addition to its core oral cancer test, the company is developing complementary assays and workflow enhancements aimed at broadening its diagnostic portfolio and supporting earlier intervention in head and neck malignancies.

Headquartered in the Pacific Northwest, Lucid Diagnostics began trading on the NASDAQ under the ticker LUCD in mid-2021 following a strategic reorganization and capital raise. The senior management team comprises professionals with backgrounds in in-vitro diagnostics, clinical laboratory operations and life-science commercialization. Looking ahead, Lucid is focused on expanding its sales footprint, advancing payer relationships and exploring international distribution agreements to extend access to its non-invasive oral cancer detection platform.

View Lucid Diagnostics Profile

More Earnings Resources from MarketBeat